Parameswaran N. Hari
Experienced in GTP Cyclohydrolase 1 Deficiency

Dr. Parameswaran N. Hari

Hematology Oncology | Hematology | Oncology
9200 W Wisconsin Ave, Hematology And Oncology, 
Milwaukee, WI 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
27 Years of Experience
Experienced in GTP Cyclohydrolase 1 Deficiency
9200 W Wisconsin Ave, Hematology And Oncology, 
Milwaukee, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Parameswaran Hari is a Hematologist Oncology specialist and a Hematologist in Milwaukee, Wisconsin. Dr. Hari has been practicing medicine for over 27 years and is rated as an Experienced provider by MediFind in the treatment of GTP Cyclohydrolase 1 Deficiency. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Primary Amyloidosis, Bone Marrow Transplant, and Splenectomy. Dr. Hari is currently accepting new patients.

His clinical research consists of co-authoring 320 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in WI
Languages Spoken
English
Hindi
Malayalam
Tamil
Urdu
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Children's Community Health
  • EPO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Network Health
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 2 Less Insurance Carriers -

Locations

9200 W Wisconsin Ave, Hematology And Oncology, Milwaukee, WI 53226

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: April 17, 2025
Intervention Type: Drug
A Phase I, Open-label, Multicenter, Study of WVT078 in Subjects With Relapsed and/or Refractory Multiple Myeloma
A Phase I, Open-label, Multicenter, Study of WVT078 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: January 09, 2025
Intervention Type: Biological, Drug
Study Drugs: WVT078, WHG626
Study Phase: Phase 1
Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma
Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Biological
Study Drugs: JCARH125, JCARH125 + Anakinra
Study Phase: Phase 1/Phase 2
A Phase 1/2, Dose Escalation Safety and Tolerability Study of AO-176 as Monotherapy and in Combination With Bortezomib and Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma
A Phase 1/2, Dose Escalation Safety and Tolerability Study of AO-176 as Monotherapy and in Combination With Bortezomib and Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: August 22, 2023
Intervention Type: Drug
Study Drugs: AO-176, AO-176 + Dex, AO-176 + Dex + Bort
Study Phase: Phase 1/Phase 2
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase 1/2a Open-label, Dose-Escalation Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Patients With Relapsed/Refractory Multiple Myeloma
A Phase 1/2a Open-label, Dose-Escalation Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Patients With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Drug
Study Drugs: TAK-079, Pomalidomide, Dexamethasone
Study Phase: Phase 1/Phase 2
An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
Enrollment Status: Approved_for_marketing
Publish Date: June 07, 2022
Intervention Type: Drug
Pilot Study of Post-thrombotic Syndrome & Predictors of Recurrence in Cancer Patients With Catheter-related Thrombosis
Pilot Study of Post-thrombotic Syndrome & Predictors of Recurrence in Cancer Patients With Catheter-related Thrombosis
Enrollment Status: Completed
Publish Date: May 18, 2022
Intervention Type: Drug
Study Phase: Not Applicable
Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20+ B Cell Lymphoma
Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20+ B Cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 11, 2021
Intervention Type: Biological
Study Drugs: ACTR707, Rituximab
Study Phase: Phase 1
A Phase 1/2, Dose Escalation, Safety and Tolerability Study of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma
A Phase 1/2, Dose Escalation, Safety and Tolerability Study of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: April 01, 2021
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
Phase I/II Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma
Phase I/II Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Study of ACTR087, an Autologous T Cell Product, in Combination With SEA-BCMA, a Monoclonal Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma
A Phase 1 Study of ACTR087, an Autologous T Cell Product, in Combination With SEA-BCMA, a Monoclonal Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: March 30, 2020
Intervention Type: Biological
Study Phase: Phase 1
A Phase II, Open-Label, Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
A Phase II, Open-Label, Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
Enrollment Status: Completed
Publish Date: October 10, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 12 Less Clinical Trials

320 Total Publications

Predictors of mortality among critically ill SARS-CoV-2 infected patients-a retrospective cohort study, Kerala, India.
Predictors of mortality among critically ill SARS-CoV-2 infected patients-a retrospective cohort study, Kerala, India.
Journal: Frontiers in public health
Published: May 26, 2025
Similar Doctors
Advanced in GTP Cyclohydrolase 1 Deficiency
Dr. Syed N. Haider
Hematology Oncology | Hematology | Oncology
Advanced in GTP Cyclohydrolase 1 Deficiency
Dr. Syed N. Haider
Hematology Oncology | Hematology | Oncology

Aurora Health Care Metro, Inc.

2900 W Oklahoma Ave, 
Milwaukee, WI 
 (5.1 miles away)
414-649-6000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Syed Haider is a Hematologist Oncology specialist and a Hematologist in Milwaukee, Wisconsin. Dr. Haider is rated as a Distinguished provider by MediFind in the treatment of GTP Cyclohydrolase 1 Deficiency. His top areas of expertise are Adult Immune Thrombocytopenia, Immune Thrombocytopenic Purpura (ITP), Hemangioma Thrombocytopenia Syndrome, and Paget Disease of the Breast. Dr. Haider is currently accepting new patients.

Shamsuddin Virani
Advanced in GTP Cyclohydrolase 1 Deficiency
Dr. Shamsuddin Virani
Hematology | Oncology
Advanced in GTP Cyclohydrolase 1 Deficiency
Dr. Shamsuddin Virani
Hematology | Oncology

Vince Lombardi Cancer Clinic

709 Spring Valley Rd, 
Burlington, WI 
 (29.7 miles away)
262-971-9200
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Offers Telehealth

Shamsuddin Virani is a Hematologist and an Oncologist in Burlington, Wisconsin. Dr. Virani is rated as a Distinguished provider by MediFind in the treatment of GTP Cyclohydrolase 1 Deficiency. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Pleuropulmonary Blastoma, and Non-Hodgkin Lymphoma.

Malik T. Bandealy
Advanced in GTP Cyclohydrolase 1 Deficiency
Dr. Malik T. Bandealy
Hematology | Oncology
Advanced in GTP Cyclohydrolase 1 Deficiency
Dr. Malik T. Bandealy
Hematology | Oncology

Vince Lombardi Cancer Clinic

6811 118th Ave, 
Kenosha, WI 
 (32.5 miles away)
262-857-5750
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Offers Telehealth

Malik Bandealy is a Hematologist and an Oncologist in Kenosha, Wisconsin. Dr. Bandealy is rated as a Distinguished provider by MediFind in the treatment of GTP Cyclohydrolase 1 Deficiency. His top areas of expertise are Angiosarcoma, Paget Disease of the Breast, Thrombocytopenia, and Adult Immune Thrombocytopenia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hari's expertise for a condition
ConditionClose
View All 26 Advanced Conditions
View All 49 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile